Country for PR: United Kingdom
Contributor: PR Newswire Europe
Tuesday, July 27 2021 - 21:00
AsiaNet
LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform
FREMONT, Calif. July 27, 2021 /PRNewswire-AsiaNet/

Further validation of ability to deliver continuous remote patient vital signs 
monitoring within both hospital and home settings.

LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval 
for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform. This 
follows recent CE marking and is further validation of LifeSignals' drive to 
create innovative wireless platforms which can be used by clinicians for the 
continuous collection of patient physiological data at home and in healthcare 
settings. 

Central to the platform is a single-use wearable multiparameter biosensor that 
records Electrocardiography (2-channel ECG), Heart Rate, Respiration Rate, Skin 
Temperature and Body Posture data for up to five days. The encrypted 
physiological data can then be transmitted with high reliability from the 
biosensor, via a relay app to a secure cloud-based platform. Clinicians and 
Care Providers can access the cloud-based remote monitoring dashboard to view 
patient physiological data and manage alert settings. 

The Remote Monitoring Platform is designed to enable healthtech companies to 
rapidly enhance their product and service portfolios to provide vital sign 
monitoring to the widest possible patient base, from any location. The relay 
app and dashboard are developer-friendly with ready-to-deploy software 
development kit APIs and is suitable for large scale implementation.

"COVID-19 has broken down the barriers to remote patient monitoring globally 
and I am proud of how the LifeSignals team has responded to develop the 
Platform in such a short space of time," says Surendar Magar, Founder and CEO. 
"This FDA 510 (k) approval marks another major milestone in the company's 
development and mission. It has already been implemented successfully in 
hospitals for monitoring COVID-19 patients in India and is being rolled out in 
Europe, UK, Singapore and the Philippines. Our focus now is to rapidly 
introduce low-cost remote vital sign monitoring to US healthtech companies 
looking to expand their services and improve patient care."

www.lifesignals.com

Photo - https://mma.prnewswire.com/media/1582121/LifeSignals.jpg 

SOURCE: LifeSignals Inc
Translations

Japanese